Купить (150 RUB)
Открытый доступ
Доступ платный или только для Подписчиков
Антикоагулянтная терапия у пациентов с фибрилляцией предсердий и хронической болезнью почек: за или против
https://doi.org/10.33667/2078-5631-2023-25-14-20
Аннотация
Фибрилляция предсердий, как и хроническая почечная недостаточность, являются распространенными состояниями среди населения, имеющие схожи факторы риска. Оба заболевания являются независимыми факторами риска развития тромбоэмболических осложнений. Существуют неопровержимые доказательства, подтверждающие преимущества антикоагулянтной терапии при фибрилляции предсердий в общей популяции, однако у пациентов с прогрессирующей хронической почечной недостаточностью возможность применения антикоагулянтов может быть ограничена. Ряд исследований показали противоречивые результаты, и данная тема представляет интерес для дальнейшего обсуждения и всестороннего анализа существующей проблемы.
Об авторах
А. Г. Комарова
ГБУЗ г. Москвы «Городская клиническая больница имени С.П. Боткина Департамента здравоохранения Москвы»
Россия
Россия
Комарова Анна Григорьевна, к.м.н., врач-кардиолог, зам. гл. врача по региональному сосудистому центру
Н. Л. Ляхова
ГБУЗ г. Москвы «Городская клиническая больница имени С.П. Боткина Департамента здравоохранения Москвы»
Россия
Россия
Ляхова Наталия Леонидовна, к.м.н., врач-кардиолог, зав. кардиологическим отделением № 4
С. Д. Кованцев
ГБУЗ г. Москвы «Городская клиническая больница имени С.П. Боткина Департамента здравоохранения Москвы»
Россия
Россия
Кованцев Сергей Дмитриевич, врач-хирург, н.с.
Е. А. Нарышкина
ГБУЗ г. Москвы «Городская клиническая больница имени С.П. Боткина Департамента здравоохранения Москвы»
Россия
Россия
Нарышкина Екатерина Александровна, врач-кардиолог
Д. В. Слепухова
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
Россия
Слепухова Диана Витальевна, врач-хирург, аспирант кафедры хирургии
Список литературы
1. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18): 2370–5.
2. Ammirati A.L. Chronic Kidney Disease. Rev Assoc Med Bras. 2020; 66 Suppl 1 (Suppl 1): s03–9.
3. Olesen J. B., Lip G. Y.H., Kamper A.-L., Hommel K., Køber L., Lane D. A., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367 (7): 625–35.
4. Wattanakit K., Cushman M., Stehman-Breen C., Heckbert S.R., Folsom A.R. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008; 19 (1): 135–40.
5. Kumar S., Lim E., Covic A., Verhamme P., Gale C.P., Camm A.J., et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74 (17): 2204–15.
6. Abdelhafiz A.H., Myint M.P., Tayek J.A., Wheeldon N.M. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther. 2009; 31 (7): 1534–9.
7. Sood M.M., Bota S.E., McArthur E., Kapral M.K., Tangri N., Knoll G., et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J kidney Heal Dis. 2014; 1: 21.
8. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europe. Eur Heart J. 2021; 42 (5): 373–498.
9. Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981–92.
10. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М. В., et al. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020.
11. Gadde S., Kalluru R., Cherukuri S. P., Chikatimalla R., Dasaradhan T., Koneti J. Atrial Fibrillation in Chronic Kidney Disease: An Overview. Cureus. 2022; 14 (8): e27753.
12. Soi V., Yee J. Sodium Homeostasis in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2017; 24 (5): 325–31.
13. Qiu H., Ji C., Liu W., Wu Y., Lu Z., Lin Q., et al. Chronic Kidney Disease Increases Atrial Fibrillation Inducibility: Involvement of Inflammation, Atrial Fibrosis, and Connexins. Front Physiol. 2018; 9: 1726.
14. Nair G.M., Nery P.B., Redpath C.J., Birnie D.H. The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation. 2014; 6 (6): 972.
15. Reil J.-C., Hohl M., Selejan S., Lipp P., Drautz F., Kazakow A., et al. Aldosterone promotes atrial fibrillation. Eur Heart J [Internet]. 2012; 33 (16): 2098–108. https://doi.org/10.1093/eurheartj/ehr266
16. Chen Z.W., Hung C.S., Wu V.C., Lin Y.H. Primary Aldosteronism and Cerebrovascular Diseases. Endocrinol Metab (Seoul, Korea). 2018; 33 (4): 429–34.
17. Nguyen V., Tu T.M., Mamauag M.J.B., Lai J., Saffari S.E., Aw T.C., et al. Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation. Front Endocrinol (Lausanne). 2022; 13: 869980.
18. Rafaqat S., Rafaqat S., Khurshid H., Rafaqat S. Electrolyte’s imbalance role in atrial fibrillation: Pharmacological management. Int J Arrhythmia [Internet]. 2022; 23 (1): 15. https://doi.org/10.1186/s42444–022–00065-z
19. Akhtar Z., Leung L. W., Kontogiannis C., Chung I., Bin Waleed K., Gallagher M.M. Arrhythmias in Chronic Kidney Disease. Eur Cardiol. 2022; 17: e05.
20. Yamagami F., Tajiri K., Yumino D., Ieda M. Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications. Toxins (Basel). 2019; 11 (10).
21. Kaartinen K., Rautavaara J., Aitkoski A., Anttonen O., Ahvonen J., Vilpakka M., et al. Fluid overload is an independent predictor of atrial fibrillation in endstage renal dise.
22. Zhou X., Dudley S.C.J. Evidence for Inflammation as a Driver of Atrial Fibrillation. Front Cardiovasc Med. 2020; 7: 62.
23. Marott S. C.W., Nordestgaard B. G., Zacho J., Friberg J., Jensen G. B., Tybjærg-Hansen A., et al. Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?: A Mendelian Randomization of 47,000 Individuals From the General Population. J Am Coll Cardiol [Internet]. 2010; 56 (10): 789–95.
24. Watanabe E., Arakawa T., Uchiyama T., Kodama I., Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol [Internet]. 2006; 108 (3): 346–53. https://doi.org/10.1016/j.ijcard.2005.05.021
25. Li J., Solus J., Chen Q., Rho Y.H., Milne G., Stein C.M., et al. Role of inflammation and oxidative stress in atrial fibrillation. Hear Rhythm [Internet]. 2010; 7 (4): 438–44. https://doi.org/10.1016/j.hrthm.2009.12.009
26. Wu N., Xu B., Xiang Y., Wu L., Zhang Y., Ma X., et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol [Internet]. 2013; 169 (1): 62–72. https://doi.org/10.1016/j.ijcard.2013.08.078
27. Matsushita N., Ishida N., Ibi M., Saito M., Takahashi M., Taniguchi S., et al. IL-1β Plays an Important Role in Pressure Overload-Induced Atrial Fibrillation in Mice. Biol Pharm Bull. 2019; 42 (4): 543–6.
28. da Silva R. M.F.L. Influence of Inflammation and Atherosclerosis in Atrial Fibrillation. Curr Atheroscler Rep [Internet]. 2017; 19 (1): 2. https://doi.org/10.1007/s11883–017–0639–0
29. Liuba I., Ahlmroth H., Jonasson L., Englund A., Jönsson A., Säfström K., et al. Source of inflammatory markers in patients with atrial fibrillation †. EP Eur [Internet]. 2008; 10 (7): 848–53. https://doi.org/10.1093/europace/eun111
30. Hu Y.-F., Chen Y.-J., Lin Y.-J., Chen S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol [Internet]. 2015; 12 (4): 230–43. https://doi.org/10.1038/nrcardio.2015.2
31. Moretti R., Janjusevic M., Fluca A.L., Saro R., Gagno G., Pierri A., et al. Common Shared Pathogenic Aspects of Small Vessels in Heart and Brain Disease. Vol. 10, Biomedicines. 2022.
32. Chen T.-H., Chu Y.-C., Ou S.-M., Tarng D.-C. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Heart [Internet]. 2022; 108 (6): 438 LP – 444. http://heart.bmj.com/content/108/6/438.abstract
33. Beyer-Westendorf J., Kreutz R., Posch F., Ay C. The CHA2DS 2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. Int J Cardiol [Internet]. 2018; 253: 71–7. https://doi.org/10.1016/j.ijcard.2017.10.110
34. Migdady I., Russman A., Buletko A. B. Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Semin Neurol. 2021; 41 (4): 348–64.
35. Gao X., Cai X., Yang Y., Zhou Y., Zhu W. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Vol. 8, Frontiers in cardiovascular medicine. Switzerland; 2021. p. 757087.
36. Noubiap J.J., Middeldorp M.E., Thomas G., Sanders P. CHA2DS2-VASc score is no longer enough-Authors’ reply. Vol. 24, Europace: European pacing, arrhythmias, and cardiac electrophysiology: Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. England; 2022. p. 1195.
37. Wang M., Zeraatkar D., Obeda M., Lee M., Garcia C., Nguyen L., et al. Drugdrug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021; 87 (11): 4051–100.
38. Марцевич С. Ю. Лукина Ю. В. Варфарин и его значение в эру новых оральных антикоагулянтов. Вопросы контроля эффективности и безопасности лечения. Рациональная фармакотерапия в кардиологии. 2017; 13 (5): 699–705.
39. Merli G. J., Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis. 2009; 27 (3): 293–9.
40. Новикова Т.Н. Особенности антикоагулянтной терапии при фибрилляции предсердий в сочетании с нарушением функции почек. Кардиология. 2021; 61 (10): 81–88. https://doi.org/10.18087/cardio.2021.10.n1767
41. Brodsky S. V., Satoskar A., Hemminger J., Rovin B., Hebert L., Ryan M. S., et al. Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases. Kidney Med. 2019; 1 (2): 51–6.
42. Brodsky S., Eikelboom J., Hebert L. A. Anticoagulant-Related Nephropathy. J Am Soc Nephrol. 2018; 29 (12): 2787–93.
43. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England). 2014; 383 (9921): 955–62.
44. Lip G.Y.H., Keshishian A., Li X., Hamilton M., Masseria C., Gupta K., et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018; 49 (12): 2933–44.
45. Vaitsiakhovich T., Coleman C.I., Kleinjung F., Vardar B., Schaefer B. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: Evidence from the real-world CALLIPER study. Curr Med Res Opin [Internet]. 2022;38 (6): 937–45. https://doi.org/10.1080/03007995.2022.2061705
46. Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis [Internet]. 2011; 31 (3): 326–43. https://doi.org/10.1007/s11239–011–0561–1
47. Kumar S., de Lusignan S., McGovern A., Correa A., Hriskova M., Gatenby P., et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: A population based study from UK primary care. BMJ. 2018; 360: k342.
48. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6 (11): 2599–604.
49. Limdi N.A., Beasley T.M., Baird M.F., Goldstein J.A., McGwin G., Arnett D.K., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009; 20 (4): 912–21.
50. Yang F., Hellyer J. A., Than C., Ullal A. J., Kaiser D. W., Heidenreich P. A., et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017; 103 (11): 818–26.
51. Malhotra K., Ishfaq M.F., Goyal N., Katsanos A.H., Parissis J., Alexandrov A.W., et al. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis. Neurology. 2019; 92 (21): e2421–31.
52. Turakhia M.P., Blankestijn P.J., Carrero J.-J., Clase C.M., Deo R., Herzog C.A., et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J[Internet]. 2018; 39 (24): 2314–25. https://doi.org/10.1093/eurheartj/ehy060
53. Tan J., Liu S., Segal J.B., Alexander G.C., McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: A systematic review and meta-analysis. BMC Nephrol. 2016; 17 (1): 157.
54. Carrero J.J., Evans M., Szummer K., Spaak J., Lindhagen L., Edfors R., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014; 311 (9): 919–28.
55. Chan K.E., Edelman E.R., Wenger J.B., Thadhani R.I., Maddux F.W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131 (11): 972–9.
56. Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H.-C., Hacke W., et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2017; 38 (27): 2137–49.
57. Di Lullo L., Magnocavallo M., Vetta G., Lavalle C., Barbera V., Ronco C. et al. [Atrial fibrillation, oral anticoagulation and nephroprotection: caution or bravery?]. G Ital Nefrol. 2022; 39 (2): 2022. Vol 2.
58. Yao X., Tangri N., Gersh B. J., Sangaralingham L. R., Shah N. D., Nath K. A., Noseworthy P. A. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017; 70 (21): 2621–2632. DOI: 10.1016/j.jacc.2017.09.1087.
59. Reinecke H., Engelbertz C., Bauersachs R., Breithardt G., Echterhoff H.H., Gerß J., et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023; 24; 147 (4): 296–309. DOI: 10.1161/circulationaha.122.062779.
60. Kuno T., Takagi H., Ando T., Sugiyama T., Miyashita S., Valentin N. et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020; 28; 75 (3): 273–285. DOI: 10.1016/j.jacc.2019.10.059.
61. Fatima H, Nwankwo I, Anam M, Maharjan S, Amjad Z, Abaza A, Vasavada AM, Sadhu A, Valencia C, Khan S. Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. Cureus. 2022; 12; 14 (10): e30230. DOI: 10.7759/cureus.30230.
Рецензия
Для цитирования:
Комарова А.Г., Ляхова Н.Л., Кованцев С.Д., Нарышкина Е.А., Слепухова Д.В. Антикоагулянтная терапия у пациентов с фибрилляцией предсердий и хронической болезнью почек: за или против. Медицинский алфавит. 2023;(25):14-20. https://doi.org/10.33667/2078-5631-2023-25-14-20
For citation:
Komarova A.G., Lyakhova N.L., Covantsev S.D., Naryshkina E.A., Slepukhova D.V. Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: Arguments for or against. Medical alphabet. 2023;(25):14-20. (In Russ.) https://doi.org/10.33667/2078-5631-2023-25-14-20
Просмотров: 19
Послать статью по эл. почте 